Simple Search Results

Query String: Nintedanib

BDBM50026612 Vargatef Nintedanib BIBF-1120 US11208381, Nintedanib US10981896, Compound Nintedanib US11046672, Nintedanib
US10669235, Nintedanib BDBM445209
BDBM734449 US20250129067, Compound Nintedanib

Roth, GJ; Binder, R; Colbatzky, F; Dallinger, C; Schlenker-Herceg, R; Hilberg, F; Wollin, SL; Kaiser, R Nintedanib: from discovery to the clinic. J Med Chem 58: 1053-63 (2015)

Inhibitory Activities of the Compounds on VEGFR2 Detect compounds on VEGFR2 (KDR) by mobility shift assay. The initial test concentration of a compound was 1000 nM, 3 times dilution, 10 concentrations, and detection in duplicate. Nintedanib (Selleckchem, Cat. S1010) was used as the positive control compound. The operation method was briefly described as follows: kinase VEGFR2 (Carna, Cat. 08-191) at the final concentration of 0.5 nM and the test compound were mixed in the Optiplate-384F well plate and incubated for 10 minutes at room temperature. Then, ATP at a final concentration of 95 μM and 3 μM Kinase substrate 22 (Gill Biochemical (glbiochem), Cat. 112393) were added. After mixing, react at room temperature for 30 minutes. Add stop detection solution to terminate the reaction and read the conversion rate with Caliper EZ ReaderlI.